Project Grant HT94252410727
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...
- The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
- The Defense Health Agency awarded The Broad Institute, Inc. a $987,600 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target chromophobe renal cell carcinoma with mono- and bi-paratopic antibody drug conjugates. The award period runs from August 1, 2024 to July 31, 2027. As a non-profit research organization, The Broad Institute will leverage its expertise in genomics, proteomics, and computational biology to conduct this innovative biomedical research...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology in Boston, Massachusetts, received a $178,999 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective May 15, 2025, with a completion date of May 14, 2026. The award supports research focused on targeting TFE3 fusion proteins using PROTAC (proteolysis-targeting chimera) technology in...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $660,937 project grant to Brigham & Women's Hospital Inc. on September 30, 2023, to support the "Identification of Novel Therapeutic Strategies for Chromophobe RCC" research project. This 3-year grant will fund basic and applied biomedical research to investigate new treatment approaches for chromophobe renal cell carcinoma, a rare form of kidney cancer. Brigham & Women's...
- This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
- This Project Grant award from the Defense Health Agency provides $979,875 to Dana-Farber Cancer Institute, Inc. for research under the Military Medical Research and Development program. The award aims to further optimize dual-targeted CAR T cells to achieve cures for advanced clear cell renal cell carcinoma (CCRCC) by fine-tuning CAR constructs against carbonic anhydrase IX and CD70 antigens based on tumor expression levels. Brigham and Women's Hospital, Inc. will receive a sub-award to...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The award supports research titled "Expanding the Targetable Tumor Antigen Repertoire of Renal Cell Carcinoma," conducted at DFCI's Boston, Massachusetts facility. This research initiative aims to identify and...
- The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...